AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Morningstar

Published November 10, 2026 · Updated November 11, 2026

MoreBetter Launches Co-Investment Program for Longevity, Peptide and Psychedelic Therapies

Read the full story at Morningstar

ketamine therapies. The RWE Co-Investment Program is open to the providers, compounding pharmacies, clinics and brands that deliver these.

Post on X

Share this story

Surfaced by 2 Google Alerts

Ketamine
Psychedelic press release